News Release

January 29, 2018
JCR Pharmaceuticals Co., Ltd.

Translation

JCR to Present at the 14th Annual WORLD*Symposium*™ 2018

JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, "JCR") announced today that oral and poster presentations on JR-141, a blood-brain barrier (BBB)-penetrating iduronate- 2-sulfatase for Hunter syndrome, and JR-051 (recombinant alpha-galactosidase A), a therapeutic enzyme for Fabry disease, will be given at the 14th Annual WORLD*Symposium*™ 2018* in San Diego (February 5 – 9, 2018).

1. **Oral presentations**
   Two oral presentations will be given for JR-141, featuring its non-clinical study results and phase I/II study results in Hunter patients. JR-141 is the first of its kind to apply JCR's proprietary BBB technology, J-Brain Cargo®.

Title	Presented on
Blood-brain barrier-penetrating iduronate-2-sulfatase reduces brain glycosaminoglycans in mouse model of mucopolysaccharidosis type II	February 7th 15:15-15:30 EST
Novel blood-brain barrier delivery system to treat CNS in MPS II - first clinical trial by anti-transferrin receptor antibody fused enzyme therapy	February 8th 11:30-11:45 EST

2. **Poster presentations**
   Two poster presentations will be given for JR-051, a therapeutic enzyme for Fabry disease as a biosimilar to agalsidase beta, featuring its non-clinical study results and phase II/III results in Fabry patients.

Title	Presented on
Efficacy and safety of JR-051, a biosimilar of agalsidase beta, in patients with Fabry disease; results of a multicenter, open-label phase 3 study in Japan	February 6th 16:30-18:30 EST
Evaluation of JR-051 as a biosimilar to agalsidase beta for Fabry disease in non-clinical studies	February 7th 16:30-18:30 EST

*WORLD*Symposium*™ is an international symposium held annually in the United States with a focus on the basic research to clinical application in the lysosomal diseases.
http://www.worldsymposia.org/

[About JCR Pharmaceuticals]
JCR is a specialty pharma engaged in the research, development, manufacture and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, "Contributing towards people's healthcare through pharmaceutical products" drives JCR to create

innovative pharmaceutical products as value-added treatment options for the under-served patient community.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jcrpharm.co.jp

END

###